CAUTIONARY STATEMENT RELATING TO THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This Quarterly Report contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this Quarterly Report may not occur.
Amphastar Pharmaceuticals, Inc. announced today that Jason Shandell, President will be presenting at the Bank of America Merrill Lynch 19 th Annual Health Care Conference on Thursday, May 12, 2016 at 9:20 a.m. Pacific Standard Time in Las Vegas, NV.. Amphastar s long-standing relationship with the major group purchasing organizations and drug
Daiichi Sankyo Co. said Friday an international arbitration court has ordered former shareholders of an Indian firm it acquired in 2008 to pay the Japanese drugmaker around 56.2 billion yen for concealing critical information about the firm. Daiichi Sankyo sold its stake in Ranbaxy Laboratories Ltd. to India's Sun Pharmaceutical Industries Ltd. las
Dublin- Research and Markets has announced the addition of the "Health& Wellness Top 10 Technologies- 2016" report to their offering. This strategic research service, Health& Wellness Top 10 Technologies, depicts the current landscape and the new trends in a series of developments associated with innovations in biosimilars, cancer screening, molecu
New Remicade Therapy Findings Has Been Reported by Investigators at University Hospital. According to news reporting from Leuven, Belgium, by NewsRx journalists, research stated, "The availability of an infliximab ELISA for measuring the originator drug Remicade and its biosimilars, such as Remsima and Inflectra, would facilitate the implementation
By a News Reporter-Staff News Editor at Drug Week Research findings on Leukocyte Disorders are discussed in a new report. According to news reporting originating from Carcassonne, France, by NewsRx correspondents, research stated, "Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment.
An Internet- based literature search through April 2015 was performed for information related to biosimilars in chronic inflammatory disorders. " The news correspondents obtained a quote from the research from the University of Nevada, "Keywords were as follows: biosimilar, development, manufacturing, characterization, structural, functional, precl
By a News Reporter-Staff News Editor at Drug Week Sunny Pharmtech Inc., a Taiwan- based API and finished-dose drug development company, and Vitruvias Therapeutics LLC, a generic drug development company, announced that they have signed two additional agreements to co-develop and market two additional high-value generic drugs. This will expand the
By a News Reporter-Staff News Editor at Drug Week Yabao Pharmaceutical Co, Inc. and Salus Pharma LLC announced a strategic partnership to co-develop, manufacture and commercialize high technological barrier generic drugs worldwide. Peng Wang, President of R&D and Head of International Business, Yabao Pharmaceutical Co. "This partnership further..
Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many important factors, including those set forth under "Risk Factors" in our Annual Report on Form 10- K for the year ended December 31, 2015. EXECUTIVE OVERVIEW ANI Pharmaceuticals, Inc. and its subsidiaries is an integrated specialt
ANI Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2016, and reaffirmed its financial guidance for 2016 as updated on April 4, 2016. The Company will host its earnings conference call this morning, May 5, 2016, at 10:30 AM ET. Thus far in 2016, we have closed three acquisitions and received two FDA app
In a recent study done by Consumer Reports National Research Center, it showcased that out of the 1,037 adults, more than a third of respondents have noticed an increase of up to $100 per prescription within a 12- month span. A study that took place in Raleigh, N.C. noticed the price of generic Cymbalta varied from store to store. For instance, the
Release date- 04052016- London- Hikma Pharmaceuticals PLC,, the fast growing multinational pharmaceutical group, announces that its supplemental Abbreviated New Drug Application for Fluphenazine Decanoate Injection USP, 125 mg/5 mL multiple-dose vial has been approved by the U.S. Food and Drug Administration. Hikma operates through three businesses
Release date- 04052016- London- Hikma Pharmaceuticals PLC,, the fast growing multinational pharmaceutical group, announces that its supplemental Abbreviated New Drug Application for Leucovorin Calcium Injection, 350 mg Single-use vial has been approved by the U.S. Food and Drug Administration. Hikma operates through three businesses:' Injectables',
CANONSBURG- Pharmaceutical company Mylan N.V. announced the U.S. launch of Hydralazine Hydrochloride Injection USP, 20 mg/mL, which is a generic version of Novartis AG's Apresoline Injection, 20 mg/mL. Hydralazine Hydrochloride Injection USP, 20 mg/mL, had U.S. sales of about $63.4 million for the 12 months ending March 31, 2016, according to IMS H
HERTFORDSHIRE, England and PITTSBURGH, May 5, 2016/ PRNewswire/ Mylan N.V. today announced the U.S. launch of Hydralazine Hydrochloride Injection USP, 20 mg/mL, which is a generic version of Novartis' Apresoline Injection, 20 mg/mL. Hydralazine Hydrochloride Injection USP, 20 mg/mL, had U.S. sales of approximately $63.4 million for the 12 months
Release date- 04052016- Mumbai- Sun Pharma today announced that two pivotal Phase-3 clinical trials evaluating the efficacy and safety of the investigational IL-23p19 inhibitor antibody tildrakizumab in patients with moderate-to-severe plaque psoriasis met their primary endpoints for both evaluated doses. The second study also included an...
Shares of Alembic Pharma closed 1.59% lower at Rs. 593.30 on BSE after the company received USFDA's approval for partial onset seizures drug. The company has received final approval from the US Food& Drug Administration for its Abbreviated New Drug Application for Lacosamide Tablets, SO mg, 100 mg, lSO mg and 200 mg.The approved ANDA is therapeut
Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its first quarter of 2016 ended March 31, 2016, after the market closes on Monday, May 9, 2016, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.. To access the conference call, dial toll free 881-2595, or 625-3083 for int
We, Mr. Sudheer Singh& Shantanu Singh, Of Taj Pharmaceuticals, Hereby Release the Clarification in Respect of our Press Release Dated 26th April, 2016 Referred Above for Ourselves and on the Behalf of Taj Pharmaceuticals. Taj Pharma Group, a Mumbai- based leading generic pharmaceutical company was accused by Emcure Pharmaceuticals of facilitating t
Coherus BioSciences, Inc., a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 11 at 9:20 am PT in Las Vegas, Nevada.. A webcast of the presentation will be available on the Investors page of the Coheru
This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements. The 1984 amendments include what is now section 505 of
Generic drug reduction notification service consignment. Tendering Authority: Japan Health Insurance Association. Tendering Authority Address: Address: Takashi matsushita, accounting division, general affairs department, japan health insurance association, 4 2 1, kudankita, chiyoda ku, tokyo, 102 8575 japan, tel 03 5212 8214.
The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. These statements may be made directly in this Quarterly Report, and they may also be made a part of this Quarterly Report by reference to oth
Impax Laboratories, Inc. is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division...